Redhill Biopharma (RDHL) Competitors $2.18 -0.01 (-0.46%) Closing price 04:00 PM EasternExtended Trading$2.14 -0.04 (-1.83%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CING, MRKR, BIVI, QTTB, MTEX, PRPH, RVPH, CARM, LPCN, and GELSShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Carisma Therapeutics (CARM), Lipocine (LPCN), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech ProPhase Labs Reviva Pharmaceuticals Carisma Therapeutics Lipocine Gelteq Cingulate (NASDAQ:CING) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Do insiders and institutionals believe in CING or RDHL? 41.3% of Cingulate shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend CING or RDHL? Cingulate presently has a consensus target price of $26.00, suggesting a potential upside of 449.68%. Given Cingulate's stronger consensus rating and higher possible upside, research analysts clearly believe Cingulate is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, CING or RDHL? Redhill Biopharma has higher revenue and earnings than Cingulate. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$8.48-0.56Redhill Biopharma$8.04M0.62-$8.27MN/AN/A Does the media favor CING or RDHL? In the previous week, Cingulate had 4 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Cingulate and 1 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 1.87 beat Cingulate's score of 0.63 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Positive Redhill Biopharma Very Positive Is CING or RDHL more profitable? Redhill Biopharma's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -229.78% -142.28% Redhill Biopharma N/A N/A N/A Which has more volatility & risk, CING or RDHL? Cingulate has a beta of -0.79, suggesting that its stock price is 179% less volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.22, suggesting that its stock price is 322% more volatile than the S&P 500. SummaryRedhill Biopharma beats Cingulate on 7 of the 12 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.00M$2.42B$5.54B$9.14BDividend YieldN/A1.70%5.01%4.00%P/E RatioN/A9.1928.6919.46Price / Sales0.62461.68373.1779.78Price / CashN/A22.3424.7227.47Price / Book-0.604.708.255.58Net Income-$8.27M$30.99M$3.19B$252.81M7 Day Performance5.83%7.18%5.59%3.24%1 Month Performance24.57%22.83%9.57%11.87%1 Year Performance-99.10%-2.60%30.64%17.60% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.18-0.5%N/A-99.1%$5.00M$8.04M0.00210Positive NewsCINGCingulate3.0818 of 5 stars$4.42+3.3%$26.00+488.2%+911.6%$18.17MN/A-0.5220Gap UpMRKRMarker Therapeutics4.522 of 5 stars$1.57-1.9%$13.17+738.6%-67.3%$18.10M$6.59M-1.1860BIVIBioVie1.0825 of 5 stars$8.10-15.6%N/A+53.9%$17.83MN/A-1.0210Positive NewsQTTBQ32 Bio2.7081 of 5 stars$1.36-5.6%$12.17+794.6%-89.9%$17.57M$1.16M-0.2839MTEXMannatech1.3943 of 5 stars$8.90-3.8%N/A+21.4%$17.49M$117.87M-89.00250High Trading VolumePRPHProPhase Labs0.5426 of 5 stars$0.44+5.6%N/A-87.1%$17.39M$6.77M-0.35130RVPHReviva Pharmaceuticals3.2637 of 5 stars$0.37+1.9%$9.00+2,353.0%-68.5%$17.28MN/A-0.465Positive NewsGap UpCARMCarisma Therapeutics3.0346 of 5 stars$0.40-2.0%$1.93+387.3%-66.7%$16.84M$19.63M-0.2520Positive NewsLPCNLipocine3.04 of 5 stars$3.11+0.3%$9.00+189.4%-57.5%$16.59M$11.20M-3.0510GELSGelteqN/A$1.67-2.9%N/AN/A$16.23M$100K0.00N/AGap Down Related Companies and Tools Related Companies Cingulate Competitors Marker Therapeutics Competitors BioVie Competitors Q32 Bio Competitors Mannatech Competitors ProPhase Labs Competitors Reviva Pharmaceuticals Competitors Carisma Therapeutics Competitors Lipocine Competitors Gelteq Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
